Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00244218 · ClinicalTrials.gov registry record · Phase 1
Response to Phenylketonuria to Tetrahydrobiopterin (BH4)
A Phase 1 study, sponsored by The University of Texas Medical Branch, Galveston.
- Terminated
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
NCT00244218 is a Phase 1 study that was terminated before completion, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 57 participants.
The verdict
NCT00244218, a Phase 1 study, was terminated before completion, sponsored by The University of Texas Medical Branch, Galveston.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether tetrahydrobiopterin (BH4)is effective in treating patients with PKU.
Interventions
- DRUG tetrahydrobiopterin (BH4)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2005-04 |
| Est. Completion | 2015-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00244218
The ClinicalTrials.gov registry entry for NCT00244218 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Medical Branch, Galveston, which has 203 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which tetrahydrobiopterin (BH4) is the first listed.
NCT00244218 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00244218 about?
NCT00244218 is a clinical study titled "Response to Phenylketonuria to Tetrahydrobiopterin (BH4)". The purpose of this study is to determine whether tetrahydrobiopterin (BH4)is effective in treating patients with PKU.
What is the current status of trial NCT00244218?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2005-04. Estimated completion is 2015-01.
What interventions are being tested in trial NCT00244218?
The interventions under investigation include: tetrahydrobiopterin (BH4) (DRUG).
Who is sponsoring clinical trial NCT00244218?
This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.